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S282 Poster Session Iproven by CT scan of chest over two winter seasons (two in 2009 and
four in 2010). Median onset of RSV pneumonia in this cohort was 18
months from the date of transplantation (range: 3 months – 8 years).
Patients were diagnosed by positive PCR assay (Three with RSV-A
and 3 with RSV-B). The rapid antigen detection test (Binaxnow, In-
verness Medical) was negative for RSV in all 6 patients. All 6 patients
were sent home from the clinic based on the negative antigen test and
were later admitted to the hospital when the PCR result was available
(range 1-3 days). Patients were treated with aerosolized Ribavirin at
a dose of 2 g. every 8 hours for 3-5 days. No complication was ob-
served other than treatment related bronchospasm that was easily
managed by concomitant inhaled bronchodilators. Most common
complaint was a feeling of claustrophobia associated with the tent
used at the time of treatment delivery. With a median follow up of
4 months (range; 1- 14 months), all patients had shown complete
clinical recovery as well as radiological improvement. There was
no relation between immune-reconstitution to the onset or severity
of the infection.
In conclusion, we recommend universal use of multiplex PCR
based technique for respiratory viral pathogens in stem cell trans-
plant recipients with respiratory symptoms over antigen based detec-
tion test. Early detection and prompt institution of therapy with
inhaled ribavirin may be responsible for 0% mortality in our cohort
compared to published literature.354
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In January of 2009, The Ohio State University Medical Center
(OSU) implemented the sepsis bundle guideline. This guideline in-
tended to provide a standard for early recognition of sepsis, provide
initial resuscitative measures, and to provide a pathway for initial
management as well as maintenance of sepsis treatment. All patients
that met initial criteria would have the sepsis bundle implemented.
With initiation of the sepsis bundle on all patients who met crite-
ria, the Blood and Marrow Transplant (BMT) Program at OSU
James Cancer Hospital reviewed their current practice for manage-
ment of these patients. Current practice is to utilize a febrile neutro-
penic pathway rather than the sepsis bundle. As it became apparent
that the sepsis bundle and the febrile neutropenic pathway were
different, a retrospective review of 30 patients was performed from
September 7, 2009 through February 10, 2010. The goal of the
review was to identify patient outcomes in those patients that met
criteria for the sepsis bundle yet were managed via the neutropenic
pathway.
Of the 30 patients reviewed, all met minimum criteria for initia-
tion of the sepsis bundle. All patients were managed via the neutro-
penic pathway rather than the sepsis bundle. In the end, 28 patients
were alive at 30 days with no complications associated with infection.
One patient was discharged to hospice related to graft failure and
multiorgan failure. The other patient developed complications
with respiratory compromise, ARDS, and multiorgan failure and
died as a result associated with ARDS.
This review suggests that BMT patients do not meet normal cri-
teria for implementation of the sepsis bundle. Ongoing discussions
continue to attempt to define specific criteria for implementation
of the sepsis bundle in the bone marrow transplant population.355
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Chemotherapy-induced nausea and vomiting (CINV) is of partic-
ular concern for patients undergoing bone marrow transplantation
(BMT) given the highly emetogenic agents used.
We conducted a retrospective observational study to verify the ef-
ficacy of our different prophylactic CINV prevention regimens for
different types of BMTperformed at our center.We looked at 78 au-
tologous and 38 allogeneic BMT patients hospitalised between au-
gust 2007 and july 2009. Patients received our standard antiemetic
prophylaxis tailored to the preparative regimen. Most patients re-
ceived a 5-HT3 antagonist and dexamethasone as prophylaxis and
prochlorperazine for breakthrough nausea. We measured emesis,
nausea and use of breakthrough antiemetics on a daily basis. Results
of the overall absence of emesis, nausea and non-use of breakthrough
antiemetics throughout the entire duration of the BMT process are
given in the following table.
Table 1. Control of nausea and emesis by preparative regimen
BEAM HD-Mel Flu-Cy TBI-Cy Bu-Cy Flu-Bu-ATGAbsence of vomiting 59.6% 29.0% 38.5% 0% 33.3% 66.7%
Absence of nausea 25.5% 6.5% 15.4% 0% 0% 50%
Non-use of
breakthrough
agents25.5% 12.9% 15.4% 0% 0% 50%In the daily evaluations, patients receiving the BEAM regimen and
the high-dose melphalan (HD-Mel) were particularly at risk of eme-
sis immediately following the melphalan. Control of CINV was ap-
proximately 90%before administration ofmelphalan and dropped to
45% on the following days.
The study included only a small number of patients in the alloge-
neic BMT setting. This group was then divided in even smaller co-
horts for each different regimen making it harder to reach
conclusions. However, all groups showed a low incidence of com-
plete control of CINV. The use of high dose cyclophosphamide
has a preparative regimen is associated with very poor nausea con-
trol.
This retrospective case study demonstrates the need to reassess
periodically the effectiveness of our prophylactic regimens for
emesis in the BMT setting and to make the appropriate changes
to improve our supportive care. Our center has changed our pro-
phylactic CINV prevention regimens and aprepitant (Emend)
has been added to some of BMT regimens even if it has not yet
received approval for this indication. Ongoing trials are assessing
its efficacy but early trials have successfully proven its safety. A
second study is planned at our center to evaluate if these modifi-
cations will improve the control of nausea and emesis in our BMT
patients.356
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Background:Hemorrhagic cystitis (HC) is a severe complication in
pediatric and adult patients (pts) undergoing allogeneic hematopoi-
etic stem cell transplantation (HCT).HC is characterized by urothe-
lial inflammation and painful hematuria which can be microscopic
(Grade I) or macroscopic with blood clots and urinary tract obstruc-
tion (grade II-IV). The incidence of HC in pediatricHCTpts ranges
from about 10% to 20 % and morbidity and mortality is as high as
75% depending on the severity of HC. The etiology of delayed onset
of HC (greater than 2 weeks from conditioning therapy) is multifac-
torial, including damage from conditioning therapy, irradiation,
graft-versus host disease (GVHD), steroids, and viral infection.
